Company Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 12/09/2024			5-day change	1st Jan Change
38.57 ^CNY	-1.08%		-3.82%	-26.74%

09-06	Gan & Lee Pharmaceuticals. announces an Equity Buyback for CNY 300 million worth of its shares.	CI
09-05	Gan & Lee Pharmaceuticals. authorizes a Buyback Plan.	CI

Business description: Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Number of employees: 4,482

Sales by Activity: Gan & Lee Pharmaceuticals.

Fiscal Period: December	2019	2020	2021	2022	2023
Development, Production and Sales of Insulin and Related Products	2.9B	3.36B	3.61B	1.71B	2.61B

See all business segments

Geographical breakdown of sales: Gan & Lee Pharmaceuticals.

Fiscal Period: December	2019	2020	2021	2022	2023
China	-	3.27B	3.36B	1.44B	2.18B
International	121M	92.81M	256M	276M	426M
Mainland China	2.77B	-	-	-	-

See all geographic segments

Managers: Gan & Lee Pharmaceuticals.

Director	Title	Age	Since
Kai Du CEO	Chief Executive Officer	47	31/12/07
Cheng Sun DFI	Director of Finance/CFO	45	19/07/20
Wei Chen BRD	Director/Board Member	44	31/12/18
Yi Wang BRD	Director/Board Member	34	30/11/16
Wei Qiang Song BRD	Director/Board Member	42	31/12/04

See GAN & LEE PHARMACEUTICALS. governance

Members of the board: Gan & Lee Pharmaceuticals.

Manager	Title	Age	Since
Zhong Ru Gan FOU	Founder	76	16/06/98
Kai Du CEO	Chief Executive Officer	47	31/12/07
Tao Zhang CHM	Chairman	46	31/12/04
Wei Qiang Song BRD	Director/Board Member	42	31/12/04
Yan Qing He BRD	Director/Board Member	39	25/04/19
Guo Jun Zheng BRD	Director/Board Member	56	25/04/19
Jia Xin Wang BRD	Director/Board Member	31	31/12/14
Lei Yin BRD	Director/Board Member	45	17/03/21
Jiao Jiao BRD	Director/Board Member	36	17/03/21
Yi Wang BRD	Director/Board Member	34	30/11/16

Composition of the Board of Directors

Shareholders: Gan & Lee Pharmaceuticals.

Name	Equities	%	Valuation
Zhong Ru Gan 33.35 %	177,135,207	33.35 %	1 021 M ¥
Qiming Venture Partners Ltd. 5.594 %	29,708,087	5.594 %	171 M ¥
Boyu Capital Advisory Co. Ltd. 3.322 %	17,643,473	3.322 %	102 M ¥
THE GOLDMAN SACHS GROUP, INC. 1.581 %	8,397,341	1.581 %	48 M ¥
Xi Ru Gan 1.172 %	6,223,276	1.172 %	36 M ¥

Name	Equities	%	Valuation
Zhong Ru Gan 41.35 %	28,508,550	41.35 %	164 M ¥
Qiming Venture Partners Ltd. 23.03 %	15,875,800	23.03 %	92 M ¥
Boyu Capital Advisory Co. Ltd. 8.381 %	5,777,913	8.381 %	33 M ¥
Hillhouse Investment Management Ltd. (Invest) 6.232 %	4,296,032	6.232 %	25 M ¥
CITIC LIMITED 6.174 %	4,256,033	6.174 %	25 M ¥

List of GAN & LEE PHARMACEUTICALS. shareholders

Company details: Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals Co., Ltd.

8 Nanfeng West 1st Road Miao County Town

101109, Beijing

http://www.ganlee.com

address Gan & Lee Pharmaceuticals.(603087)

Biopharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GAN & LEE PHARMACEUTICALS.	-1.08%	-3.82%	-10.80%	-50.10%	3.27B
CSL LIMITED	+0.38%	-0.54%	+12.31%	-0.12%	96.47B
SAMSUNG BIOLOGICS CO.,LTD.	-1.02%	+2.64%	+32.29%	+4.97%	52.11B
UCB	+1.24%	-0.67%	+97.95%	+78.89%	33.66B
BIOGEN INC.	-0.60%	-1.94%	-23.43%	-33.99%	29B
BIOMARIN PHARMACEUTICAL INC.	-0.47%	-0.87%	-8.34%	+8.21%	16.14B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.26%	-1.75%	+37.64%	-26.65%	12.27B
INCYTE CORPORATION	+0.36%	+0.64%	-1.35%	-10.91%	12.16B
ALTEOGEN INC.	+3.27%	+2.76%	+508.86%	+375.19%	12.13B
SWEDISH ORPHAN BIOVITRUM AB	+0.75%	+4.36%	+45.25%	+32.64%	10.51B
Average	+0.14%	+0.00%	+69.04%	+37.81%	27.77B
Weighted average by Cap.	+0.07%	-0.54%	+44.69%	+22.76%